These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 28905886)
1. Time-series oligonucleotide count to assign antiviral siRNAs with long utility fit in the big data era. Wada K; Wada Y; Iwasaki Y; Ikemura T Gene Ther; 2017 Oct; 24(10):668-673. PubMed ID: 28905886 [TBL] [Abstract][Full Text] [Related]
2. Directional and reoccurring sequence change in zoonotic RNA virus genomes visualized by time-series word count. Wada Y; Wada K; Iwasaki Y; Kanaya S; Ikemura T Sci Rep; 2016 Nov; 6():36197. PubMed ID: 27808119 [TBL] [Abstract][Full Text] [Related]
3. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs. Wagner A; Bock CT; Fechner H; Kurreck J Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598 [No Abstract] [Full Text] [Related]
4. A web-based resource for designing therapeutics against Ebola Virus. Dhanda SK; Chaudhary K; Gupta S; Brahmachari SK; Raghava GP Sci Rep; 2016 Apr; 6():24782. PubMed ID: 27113850 [TBL] [Abstract][Full Text] [Related]
5. Design and screening of siRNAs against highly structured RNA targets. Nasheri N; Pezacki JP; Sagan SM Methods Mol Biol; 2013; 942():69-86. PubMed ID: 23027046 [TBL] [Abstract][Full Text] [Related]
6. Viral small RNA cloning and sequencing. Gausson V; Saleh MC Methods Mol Biol; 2011; 721():107-22. PubMed ID: 21431681 [TBL] [Abstract][Full Text] [Related]
7. A potential therapeutic for pandemic influenza using RNA interference. Seth S; Templin MV; Severson G; Baturevych O Methods Mol Biol; 2010; 623():397-422. PubMed ID: 20217566 [TBL] [Abstract][Full Text] [Related]
8. Gene silencing: a therapeutic approach to combat influenza virus infections. Khanna M; Saxena L; Rajput R; Kumar B; Prasad R Future Microbiol; 2015; 10(1):131-40. PubMed ID: 25598342 [TBL] [Abstract][Full Text] [Related]
9. VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses. Qureshi A; Thakur N; Kumar M J Transl Med; 2013 Dec; 11():305. PubMed ID: 24330765 [TBL] [Abstract][Full Text] [Related]
10. One long oligonucleotide or two short oligonucleotides based shRNA construction and expression. Wang XJ; Wang SQ Methods Mol Biol; 2015; 1218():37-41. PubMed ID: 25319644 [TBL] [Abstract][Full Text] [Related]
11. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492 [TBL] [Abstract][Full Text] [Related]
13. Nucleic acid-based drugs against emerging zoonotic viruses. Wong JP Future Med Chem; 2015; 7(13):1709-19. PubMed ID: 26399689 [TBL] [Abstract][Full Text] [Related]
14. VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Thakur N; Qureshi A; Kumar M Nucleic Acids Res; 2012 Jan; 40(Database issue):D230-6. PubMed ID: 22139916 [TBL] [Abstract][Full Text] [Related]
15. Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. Dave RS; Pomerantz RJ J Virol; 2004 Dec; 78(24):13687-96. PubMed ID: 15564478 [TBL] [Abstract][Full Text] [Related]
16. A novel program to design siRNAs simultaneously effective to highly variable virus genomes. Lee HS; Ahn J; Jun EJ; Yang S; Joo CH; Kim YK; Lee H Biochem Biophys Res Commun; 2009 Jul; 384(4):431-5. PubMed ID: 19422797 [TBL] [Abstract][Full Text] [Related]